Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being eva... Read more
Cellares
4 followers
Tango Therapeutics
3 followers
Dyno Therapeutics
4 followers
Odyssey Therapeutics
2 followers
Gilead Sciences
161 followers
Regeneron
132 followers
Illumina
79 followers
Agilent Technologies
82 followers
Verily Life Sciences
45 followers
Alexion Pharmaceuticals
45 followers
GRAIL
29 followers
Explore companies